What this study is
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
Study details
- Official title
- A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US
- Sponsor
- Janssen Research & Development, LLC
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Enrolling
- 150 people
- Starts
- 2026-06-12
- Est. completion
- 2030-06-28
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy
- Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit/Study visit 1
- Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice
- Must provide informed consent as described in the protocol
You can't join if
- Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment
- Had previous treatment with TAR-200 discontinued prior to baseline visit/Study visit 1
- Previously received TAR-200 intravesically as part of a clinical trial(s)
- Previously received greater than (>) 2 doses/cycles of TAR-200 in the real-world setting
- Currently participating in an interventional bladder cancer clinical trial
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (23)
23 openUniversity of Alabama at Birmingham
Birmingham, Alabama, United States
RecruitingMayo Clinic 1
Phoenix, Arizona, United States
RecruitingArkansas Urology
Little Rock, Arkansas, United States
RecruitingUSC Norris Comprehensive Cancer Center
Los Angeles, California, United States
RecruitingCedars Sinai Medical Center
Los Angeles, California, United States
RecruitingColorado Clinical Research
Lakewood, Colorado, United States
RecruitingMayo Clinic
Jacksonville, Florida, United States
RecruitingFlorida Urology Partners
Wimauma, Florida, United States
RecruitingAssociated Urological Specialists
Chicago Ridge, Illinois, United States
RecruitingIndiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
RecruitingFrederick Health
Frederick, Maryland, United States
RecruitingMichigan Institute of Urology
Troy, Michigan, United States
RecruitingMayo Clinic Rochester
Rochester, Minnesota, United States
RecruitingSpecialty Clinical Research of St Louis
St Louis, Missouri, United States
RecruitingSUNY Upstate Med Univ
Syracuse, New York, United States
RecruitingUrology Specialists of the Carolinas PLLC Charlotte
Charlotte, North Carolina, United States
RecruitingMidLantic Urology - Haverford Road - Bryn Mawr
Bryn Mawr, Pennsylvania, United States
RecruitingLow Country Urology Clinics
North Charleston, South Carolina, United States
RecruitingUrology Specialists of South Dakota
Sioux Falls, South Dakota, United States
RecruitingUPNT Research Institute
Arlington, Texas, United States
RecruitingUT Southwestern Medical Center
Dallas, Texas, United States
RecruitingUniversity of Washington School of Medicine
Seattle, Washington, United States
RecruitingSpokane Urology
Spokane, Washington, United States
Recruiting
Study team
Sponsor
Janssen Research & Development, LLC
Study ID 17000139BLC4004
Study director
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.